| Lung Cancer |
1 |
1 |
| Skin Cancer |
0 |
0.98 |
| Biologic Therapy |
0 |
0.8 |
| Genomic Medicine |
0 |
0.67 |
| Antineoplastic Drug |
0 |
0.66 |
| Non-Small Cell Lung Cancer |
0 |
0.66 |
| Cancer |
0 |
0.55 |
| Small Cell Lung Cancer |
0 |
0.53 |
| Anaplastic Lymphoma Kinase |
0 |
0.48 |
| ALK Inhibitor |
0 |
0.42 |
| Drug Costs |
0 |
0.36 |
| EGFR Inhibitor |
0 |
0.32 |
| Melanoma |
0 |
0.29 |
| BRAF |
0 |
0.27 |
| Lung |
0 |
0.27 |
| Lymphoma |
0 |
0.27 |
| Tyrosine Kinase Inhibitor |
0 |
0.27 |
| BRAF Inhibitor |
0 |
0.26 |
| Epidermal Growth Factor Receptor |
0 |
0.26 |
| Receptors |
0 |
0.18 |
| Food and Drug Administration (FDA) |
0 |
0.09 |
| Generics |
0 |
0.09 |
| Immunotherapy |
0 |
0.09 |
| Off-Label Use |
0 |
0.09 |
| Prescription Drugs |
0 |
0.09 |